Lysogene Reports Second Quarter Cash Position and Provides

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
31
Lysogene Reports Second Quarter Cash Position and Provides Business and Strategic Update

CAMBRIDGE, Mass. and PARIS, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today reports its cash position for the second quarter 2018 and provides a business as well as a strategic update.

Cash position as of June 30, 2018

As of June 30, 2018, cash and cash equivalent amounted to €8.16 million, compared to €9.9 million on March 31, 2018. The Company’s cash position allows the Company to cover its anticipated needs until November 2018, based on the company's current operational development plan. Lysogene did not generate revenues during the second quarter 2018.

Business update

Update on recent manufacturing and clinical progress with LYS-SAF302, a Phase 2/3 drug candidate for the treatment of MPS IIIA

As planned, Lysogene has made significant progress regarding the preparation of the Phase 2/3 Pivotal study with LYS-SAF302. Most recent progress include the successful production of clinical batches, with batch release activities currently on going.

All plans to activate eight clinical sites in the U.S. and Europe for this trial remain underway, in order to enable maximum patient access to the Company’s novel gene therapy treatment, the first Phase 2/3 MPS IIIA drug candidate worldwide.

Update on Lysogene’s second asset, LYS-GM101, drug candidate for the treatment of GM1 and recent collaboration for Fragile X syndrome

Lysogene’s IND-enabling preclinical study program in GM1 Gangliosidosis is progressing and the Company intends to report long-term results in the second half of 2018.

Scientific Advice/Protocol Assistance meeting with the European Medicines Agency was held on June 11, 2018. The EMA Final Advice Letter provides valuable guidance for Lysogene on preclinical, clinical and manufacturing considerations. Most importantly, the EMA accepted the adaptive design proposal from Lysogene.

Together with the future Pre-IND meeting with the U.S. Food and Drug Administration, these regulatory interactions should enable Lysogene to further define the optimal development plan for this new innovative therapy.

The activities related to the Fragile X Syndrome gene therapy program developed in collaboration with Dr Herve Lemoine progressed.

The implementation of each of these programs will depend on the financial capabilities of the Company.

Strategic Update

Given the current cash runway of the Company, the Company has decided to focus its efforts on the conclusion of a strategic partnership or transaction, or potential sale of one or several products. The Company has retained Torreya to serve as its financial advisor in this process.

Lysogene does not have a defined timeline yet for such potential transactions and will disclose future developments, as the case may be, as soon as appropriate.

The Company is also currently working on cost containment measures in order to reduce its cash burn, and will communicate on the progress of the above in more detail in Q3 2018.

Attention of the public is drawn to the risk factors presented in the 2017 registration document ( Document de référence ), registered with the French Markets Authorities on June 4, 2018, under number R. 18-047, and in particular to the liquidity risk and risk associated to the dependence to a successful development of LYS-SAF 302 as set out in paragraphs 4.2.2 and 4.4.2 of the 2017 registration document ( Document de référence ).

About Lysogene Lysogene is a gene therapy company focused on the treatment of orphan diseases of the central nervous system (CNS). The company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A pivotal clinical trial in MPS IIIA and a phase 1-2 clinical trial in GM1 Gangliosidosis are in preparation, while we are currently collaborating with a major partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. www.lysogene.com

Contact

Julie Coulot / Emmanuel Huynh   Chris Maggos    
NewCap   LifeSci Advisors    
lysogene@newcap.eu   chris@lifesciadvisors.com    
+ 33 1 44 71 94 95   +41 79 367 6254    
Stéphanie Leouzon
Torreya / + 44 (0) 207 451 4551 
stephanie.leouzon@torreya.com

Forward looking statement This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company’s control and (iii) the financial capabilities of the Company. These statements may include, without limitation, any statements preceded by, followed by or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could” and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, including in the 2017 registration document ( Document de référence ), registered with the French Markets Authorities on June 4, 2018, under number R. 18-047, and future filings and reports by the Company. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Lysogene in any country. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Roland DG's Brand Refresh Earns Three B2B Awards in 2026

Updated Category News Views 98

Three trophies for a printer-maker’s marketing overhaul will not move mountains by themselves, but they do tell us Roland DG has stopped treating its brand like an afterthought. The company’s global Make Your Mark refresh picked up two Silver awards and one Bronze at the 2026 Drum B2B Awards in Miami. For a business selling industrial-grade tools into crowded,...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Hyster-Yale's $125 Million Convertible Debt Shuffle

Updated Category News Views 142

Forklifts do not make headlines often, but debt terms sure can. Hyster-Yale has proposed a $125 million private offering of convertible senior notes due November 15, 2031, with buyers able to take another $18.75 million if the initial purchasers exercise their option. For NYSE:HY holders, this is not a victory lap or a distress flare by itself. It is a refinancing...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 77

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
BKV Energy's $400,000 Loyalty Bet Has a Real Point Behind It

Updated Category News Views 92

Retail power customers rarely send thank-you notes; they switch plans, complain about bills, or quietly vanish. That is why BKV Energy putting more than $400,000 into its third annual ElectroShare payout deserves a harder look than the usual feel-good loyalty announcement. A Retention Expense With Some Teeth The payout has climbed quickly: roughly $113,000 in the first...

Continue Reading
Polsen Flex Deal Puts Pre-Tax Funds Behind Wearables

Updated Category News Views 141

A pile of soon-to-expire FSA cash is a peculiar sales catalyst, but Polsen Health has found one. The Amsterdam-based preventative-health wearable company is partnering with Flex to let customers pay for every Polsen watch and strap using eligible HSA or FSA funds at checkout. No reimbursement chase, no claim forms, and buyers can split the cost with another card. For a...

Continue Reading
MetaOptics Tests a Real Path Into Secure Imaging Markets

Updated Category News Views 84

Fingerprint scanners have never impressed me much; fooling one is exactly the sort of nuisance that keeps security buyers spending. MetaOptics’ new collaboration with Hong Kong’s ASTRI goes after that uncomfortable problem with a compact nano-optics imaging system built for biometric security and smart sensing. It is a sensible target. It is also, at this stage, a...

Continue Reading
Seeking Alpha Premium Review: Data Meets Human Judgment

Updated Category News Views 159

A spreadsheet can spot a cracked windshield, but it cannot tell you where the truck is headed. That is the useful, slightly irritating truth behind Seeking Alpha Premium’s 2026 pitch: it puts an enormous amount of stock-research machinery in one place, yet the investor still has to do the driving. Software Experts has highlighted the service in its review of...

Continue Reading
Teachers in Space Takes Its Classroom Model Orbital

Updated Category News Views 114

Two teachers strapped into a research flight may sound like a glossy space-age photo op, but the useful part of this plan sits back in the classroom with the students staring at the data. Teachers in Space wants to send two educators aboard a Virgin Galactic research flight expected in 2027, and it is raising $2 million to fund the broader educational program and mission....

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 121

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading

Top 5 Most Recently Viewed Articles

BW Offshore Announces Ex Dividend of USD 0.0625 for Shareholders

Updated Category News Views 145

BW Offshore Announces Ex Dividend for Shareholders BW Offshore Limited is excited to announce that its shares will be trading ex dividend at USD 0.0625 per share. This important announcement marks the beginning of a new dividend cycle for our valued shareholders. Upcoming Dividend Payment The dividend payment is scheduled to occur around November 28, ensuring that our...

Continue Reading
Empowering the Hispanic Community in Home Buying Efforts

Updated Category News Views 93

Sun Title Launches Initiative for Hispanic Home Buyers In a notable move to foster inclusivity in the real estate market, Sun Title has introduced a comprehensive initiative aimed at empowering Hispanic home buyers and sellers. This effort is designed to support individuals in the Hispanic community, helping them navigate the often complex processes involved in buying or...

Continue Reading
Fluence Energy Delivers Impressive Q4 Results and Growth Insights

Updated Category News Views 312

Fluence Energy Q4 Earnings Overview Fluence Energy (NASDAQ: FLNC) recently shared its earnings results for the fourth quarter, bringing forth exciting news for investors. The performance exceeded expectations, indicating positive upward momentum. Highlights from the Earnings Call In an announcement made recently, Fluence Energy reported an earnings per share (EPS) of...

Continue Reading
How Buck Sexton Highlights Leadership in the AI Arms Race

Updated Category News Views 287

The Urgency of the AI Arms Race In a recent interview, former CIA officer Buck Sexton shared alarming insights into America's current position in the race for Artificial Superintelligence. He emphasizes that this is not just about technology, but about America's future as a global leader. He suggests that we are currently in a precarious situation, as other nations,...

Continue Reading
Finastra Gains Leader Spot in Digital Banking 2026

Updated Category News Views 48

When it comes to digital banking, not every player gets the spotlight, but Finastra? They're not just basking in it—they're standing on top of the podium as a Leader in the SPARK Matrix™: Digital Banking Platform 2026 by QKS Group. Why Finastra Shines Bright Now, Finastra ain't some overnight sensation. They’ve been hammering away at the digital banking world with...

Continue Reading